君实生物(01877.HK)特瑞普利单抗新适应症上市申请获批

阿斯达克财经
Yesterday

君实生物(01877.HK) 公布,特瑞普利单抗(商品名:拓益)用于不可切除或转移性黑色素瘤的一线治疗的新适应症上市申请获国家药品监督管理局批准。这是特瑞普利单抗在内地获批的第12项适应症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-25 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10